gadopentetátdimeglumine

Gadopentetate dimeglumine is a contrast agent used in magnetic resonance imaging (MRI). It is a gadolinium-based contrast agent (GBCA) that enhances the visibility of certain tissues and abnormalities within the body. The agent is administered intravenously before the MRI scan.

The active ingredient, gadolinium, is a paramagnetic metal ion. When introduced into the body, it alters the magnetic properties of water molecules. This alteration results in a shortened relaxation time of protons in water, leading to a brighter signal on T1-weighted MRI images. This increased signal intensity helps to differentiate between normal and abnormal tissues, such as tumors, inflammation, or vascular malformations.

Gadopentetate dimeglumine is supplied as a solution for injection and is available in various concentrations. The dosage and administration depend on the type of MRI examination and the patient's weight and kidney function. It is important for healthcare providers to assess kidney function before administering GBCA's due to the risk of nephrogenic systemic fibrosis (NSF) in patients with severe renal impairment.

Following administration, gadopentetate dimeglumine is distributed in the extracellular space and is primarily excreted unchanged by the kidneys. Common side effects are generally mild and transient, including nausea, headache, and dizziness. Allergic reactions, though rare, can occur. Healthcare professionals carefully weigh the benefits of enhanced diagnostic information against the potential risks when deciding to use this contrast agent.